Abstract
Overview
Introduction
This analysis examines the historical and forecast performance for Wyeth in
the ethical pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Reasons to Purchase
- Benchmark Wyeth' s performance against key rivals in the ethical
pharmaceutical sector
- Analyze how Wyeth will perform in light of patent expiry for the key
Effexor and Protonix franchises prior to 2012
- Assess the forecast transition in Wyeth' s therapeutic focus, as
illustrated by the emergence of its infectious diseases portfolio
View Cart
